Life sciences and technology companies supported by the OBIO's CAAP have collectively raised more than $1bn in capital.

AstraZeneca has agreed to invest $2bn in newly issued equity in Summit Therapeutics to develop combination therapies using the bispecific antibody ivonescimab and ADCs across multiple tumour types.

Juvmo was designed to offer a reduction in motor symptoms, while reducing non-motor side effects, through its more selective mechanism.

Tolerance Bio has signed an agreement securing an exclusive licence from Tanabe Pharma for TLB-33 in a deal of up to around $560m.

As OEB6 increasingly appears in HPAPI and ADC manufacturing, the key question is whether pharmaceutical pipelines actually require a new exposure band — or whether the label is becoming commercial ...

From patient-centric designs and sustainable changes to component shortages, anti-counterfeiting, and low-volume production, sponsors of OSD products are navigating a number of packaging trends and ...

Despite Dr Heidi Overton’s declaration, senators questioned whether the commissioner-elect would challenge erroneous statements from president Trump.

Novo is shaping a future beyond its Wegovy franchise as CEO Maziar Mike Doustdar looks to turn the drugmaker’s fortunes around.

Sandoz’s chief commercial officer discusses the company’s ambitious plans to have a biosimilar-driven growth engine by 2040.

The deal reflects a growing interest from big pharma in the compounds that bridge the gap between small molecules and biologics.

Novo will harness Anthropic’s AI assistant Claude to accelerate research and development (R&D) activities, as the drugmaker looks to regain its once-dominant position at the fro ...

Biopharma firms are increasingly choosing to manufacture their newer FDA-approved innovator and biosimilar products at facilities in China.